Zara M Patel, MD
Otolaryngology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Patel’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A112083 · Current
Licensed to practise in California · since 2010 · expires 2027-09-30 · Oregon Health Sciences University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$75,414
Medicare paid this office $75,414 for 175 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Biopsy or removal of nasal polyp or tissue using an endoscope | 34 | $9,279 | $193 |
| Diagnostic exam of nasal passages using an endoscope | 118 | $8,046 | $55 |
| New patient visit (60+ min) | 53 | $7,848 | $148 |
| Removal of tissue from sphenoid sinus using an endoscope | 13 | $7,679 | $591 |
| Return visit (30+ min) | 60 | $5,802 | $82 |
See all 13 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 34 | $9,279 | $193 |
| Diagnostic exam of nasal passages using an endoscope | 118 | $8,046 | $55 |
| New patient visit (60+ min) | 53 | $7,848 | $148 |
| Removal of tissue from sphenoid sinus using an endoscope | 13 | $7,679 | $591 |
| Return visit (30+ min) | 60 | $5,802 | $82 |
| Exploration of nasal sinus using an endoscope | 13 | $5,198 | $400 |
| Long return visit (40+ min) | 36 | $4,892 | $122 |
| Reshaping of nasal cartilage | 14 | $4,745 | $339 |
| Removal of nasal sinus tissue using an endoscope | 16 | $3,908 | $244 |
| Computer-assisted procedure outside membrane covering brain | 15 | $2,281 | $152 |
| New patient visit (45+ min) | 22 | $2,278 | $104 |
| Removal of nasal air passage under lining tissue | 11 | $1,266 | $115 |
| Short return visit (20+ min) | 14 | $834 | $60 |
Who their Medicare patients are
175 Original Medicare patients in 2024. Average age 71 · Women 57% · Also on Medicaid 20% · Health risk score 1.26. Above the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 59% · Diabetes 26% · Coronary heart disease 25% · Depression 19% · Cancer 18% · COPD 16% · Chronic kidney disease 15% · Atrial fibrillation 13% · Heart failure 11% · Stroke 7%.
The office billed $662,634, Medicare allowed $98,788 and paid $75,414; for 519 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 175 | 519 | 71 | 1.26 | $662,634 | $75,414 |
| 2023 | 168 | 521 | 71 | 1.24 | $557,438 | $68,529 |
| 2022 | 173 | 528 | 72 | 1.19 | $575,654 | $75,501 |
| 2021 | 167 | 583 | 70 | 1.17 | $709,110 | $83,026 |
| 2020 | 140 | 468 | 70 | 1.41 | $611,433 | $59,515 |
| 2019 | 142 | 500 | 71 | 1.37 | $710,563 | $66,416 |
| 2018 | 172 | 691 | 69 | 1.51 | $870,306 | $89,809 |
| 2017 | 175 | 758 | 69 | 1.48 | $1,295,442 | $112,868 |
| 2016 | 141 | 537 | 69 | 1.28 | $723,036 | $77,048 |
| 2015 | 113 | 319 | 68 | 1.40 | $279,763 | $43,273 |
| 2014 | 145 | 516 | 68 | 1.28 | $481,203 | $82,061 |
| 2013 | 124 | 347 | 68 | 1.35 | $341,200 | $66,212 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 33 | $9,309 | $198 |
| Diagnostic exam of nasal passages using an endoscope | 134 | $6,812 | $38 |
| New patient visit (60+ min) | 41 | $6,641 | $162 |
| Return visit (30+ min) | 51 | $5,588 | $86 |
| Reshaping of nasal cartilage | 12 | $5,581 | $465 |
| Long return visit (40+ min) | 40 | $5,219 | $121 |
| Exploration of nasal sinus using an endoscope | 12 | $4,685 | $390 |
| Removal of nasal sinus tissue using an endoscope | 13 | $3,475 | $267 |
| New patient visit (45+ min) | 29 | $3,381 | $117 |
| Computer-assisted procedure outside membrane covering brain | 13 | $2,207 | $158 |
| Short return visit (20+ min) | 11 | $732 | $61 |
2022: 9 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 41 | $11,682 | $198 |
| Return visit (30+ min) | 66 | $7,147 | $84 |
| Reshaping of nasal cartilage | 11 | $6,572 | $597 |
| New patient visit (60+ min) | 34 | $5,368 | $158 |
| Long return visit (40+ min) | 39 | $5,173 | $123 |
| New patient visit (45+ min) | 33 | $3,769 | $114 |
| Diagnostic exam of nasal passages using an endoscope | 124 | $3,511 | $24 |
| Removal of nasal sinus tissue using an endoscope | 14 | $3,057 | $218 |
| Computer-assisted procedure outside membrane covering brain | 16 | $2,513 | $157 |
2021: 10 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 40 | $11,455 | $201 |
| New patient visit (60+ min) | 42 | $7,237 | $172 |
| Reshaping of nasal cartilage | 15 | $7,138 | $476 |
| Return visit (30+ min) | 59 | $6,969 | $85 |
| Exploration of nasal sinus using an endoscope | 15 | $5,985 | $399 |
| Long return visit (40+ min) | 40 | $5,290 | $123 |
| Diagnostic exam of nasal passages using an endoscope | 139 | $3,953 | $22 |
| New patient visit (45+ min) | 30 | $3,586 | $120 |
| Removal of nasal sinus tissue using an endoscope | 14 | $3,533 | $252 |
| Computer-assisted procedure outside membrane covering brain | 16 | $2,537 | $159 |
2020: 9 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 34 | $10,939 | $192 |
| New patient visit (45+ min) | 41 | $4,489 | $109 |
| Return visit (30+ min) | 40 | $3,127 | $67 |
| Diagnostic exam of nasal passages using an endoscope | 109 | $2,804 | $20 |
| Removal of nasal sinus tissue using an endoscope | 11 | $2,774 | $252 |
| Long return visit (40+ min) | 12 | $1,255 | $105 |
| Short return visit | 30 | $1,001 | $22 |
| New patient visit (30+ min) | 13 | $839 | $65 |
| Short return visit (20+ min) | 15 | $728 | $46 |
2019: 10 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 39 | $11,789 | $187 |
| Diagnostic exam of nasal passages using an endoscope | 122 | $6,011 | $41 |
| Exam of nose and sinus with removal of nasal sinus using an endoscope | 11 | $4,060 | $369 |
| Exploration of nasal sinus using an endoscope | 16 | $3,619 | $226 |
| Return visit (30+ min) | 48 | $3,567 | $69 |
| New patient visit (45+ min) | 30 | $3,235 | $108 |
| Computer-assisted procedure outside membrane covering brain | 13 | $2,200 | $157 |
| New patient visit (30+ min) | 28 | $1,665 | $59 |
| Short return visit | 40 | $976 | $20 |
| Short return visit (20+ min) | 13 | $650 | $46 |
2018: 13 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 33 | $12,842 | $189 |
| Diagnostic exam of nasal passages using an endoscope | 147 | $10,970 | $51 |
| Exam of nose and sinus with removal of nasal sinus using an endoscope | 13 | $7,045 | $542 |
| Exploration of nasal sinus using an endoscope | 23 | $5,476 | $238 |
| New patient visit (45+ min) | 47 | $4,975 | $106 |
| Reshaping of nasal cartilage | 13 | $4,682 | $360 |
| Return visit (30+ min) | 50 | $3,549 | $61 |
| Computer-assisted procedure outside membrane covering brain | 22 | $3,298 | $150 |
| Short return visit | 60 | $1,827 | $22 |
| Removal of nasal sinus tissue using an endoscope | 12 | $1,774 | $148 |
| Incision of nasal sinus using an endoscope | 15 | $1,615 | $108 |
| New patient visit (30+ min) | 24 | $1,563 | $65 |
| Short return visit (20+ min) | 17 | $783 | $44 |
2017: 13 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 54 | $16,167 | $174 |
| Exploration of nasal sinus using an endoscope | 24 | $14,379 | $599 |
| Diagnostic exam of nasal passages using an endoscope | 155 | $12,886 | $54 |
| New patient visit (45+ min) | 54 | $5,898 | $109 |
| Removal of nasal sinus using an endoscope | 23 | $5,712 | $248 |
| Removal of nasal air passage under lining tissue | 13 | $4,765 | $367 |
| Return visit (30+ min) | 55 | $4,361 | $68 |
| Computer-assisted procedure outside membrane covering brain | 20 | $3,119 | $156 |
| Incision of sphenoid nasal sinus using an endoscope | 19 | $2,812 | $148 |
| Incision of nasal sinus using an endoscope | 17 | $2,048 | $120 |
| New patient visit (30+ min) | 29 | $1,833 | $63 |
| Short return visit | 31 | $886 | $23 |
| Short return visit (20+ min) | 13 | $593 | $46 |
2016: 9 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 33 | $11,810 | $187 |
| Diagnostic exam of nasal passages using an endoscope | 124 | $9,324 | $56 |
| Exploration of nasal sinus using an endoscope | 15 | $8,164 | $544 |
| New patient visit (45+ min) | 56 | $6,080 | $109 |
| Removal of nasal sinus using an endoscope | 14 | $3,299 | $236 |
| Return visit (30+ min) | 39 | $3,292 | $69 |
| New patient visit (30+ min) | 32 | $1,966 | $61 |
| Incision of sphenoid nasal sinus using an endoscope | 11 | $1,577 | $143 |
| Short return visit (20+ min) | 27 | $1,102 | $38 |
2015: 8 services
| Diagnostic exam of nasal passages using an endoscope | 59 | $10,612 | $147 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 23 | $6,827 | $195 |
| Diagnostic exam of nasal passages using an endoscope | 27 | $1,655 | $59 |
| Return visit (30+ min) | 17 | $1,431 | $65 |
| New patient visit (45+ min) | 12 | $1,389 | $116 |
| New patient visit (45+ min) | 11 | $1,084 | $99 |
| New patient visit (30+ min) | 12 | $817 | $68 |
| Short return visit (20+ min) | 16 | $751 | $44 |
2014: 10 services
| Diagnostic exam of nasal passages using an endoscope | 105 | $22,117 | $154 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 35 | $13,548 | $208 |
| Removal of growth of pituitary using an endoscope | 15 | $12,107 | $807 |
| New patient visit (45+ min) | 40 | $4,907 | $123 |
| Return visit (30+ min) | 33 | $2,527 | $72 |
| Removal of nasal sinus using an endoscope | 11 | $2,422 | $220 |
| Removal of nasal sinus tissue using an endoscope | 14 | $2,187 | $156 |
| Diagnostic exam of voice box using a flexible endoscope | 15 | $1,497 | $88 |
| New patient visit (30+ min) | 16 | $1,319 | $82 |
| Short return visit (20+ min) | 22 | $1,150 | $50 |
2013: 8 services
| Diagnostic exam of nasal passages using an endoscope | 95 | $19,579 | $165 |
| Removal of growth of pituitary using an endoscope | 15 | $11,940 | $796 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 19 | $8,402 | $300 |
| New patient visit (45+ min) | 25 | $3,147 | $126 |
| Return visit (30+ min) | 36 | $3,069 | $75 |
| Diagnostic exam of voice box using a flexible endoscope | 20 | $2,163 | $77 |
| Short return visit (20+ min) | 17 | $883 | $52 |
| New patient visit (30+ min) | 13 | $857 | $66 |
Medicaid work
$3,803 in 2024
Medicaid paid $3,803 for 114 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 114 | $3,803 |
| 2024 | 114 | 1 | 16 | $3,803 |
| 2023 | 49 | 1 | 13 | $1,309 |
| 2022 | 121 | 2 | 20 | $2,653 |
| 2021 | 198 | 1 | 19 | $4,459 |
| 2020 | 78 | 1 | 19 | $1,649 |
| 2019 | 201 | 1 | 21 | $5,994 |
| 2018 | 210 | 1 | 20 | $7,120 |
See the largest Medicaid services in earlier years
2023
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 49 | $1,309 |
2022
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 109 | $2,346 |
| Return visit (30+ min) | 12 | $306 |
2021
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 198 | $4,459 |
2020
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 78 | $1,649 |
2019
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 201 | $5,994 |
2018
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 210 | $7,120 |
Drugs they prescribed that Part D paid
$705
Pharmacies billed $705 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
42 generic and 0 brand-name prescriptions · $705 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Azelastine | 13 | $240 | $18 |
Year by year
| 2024 | 42 | 18 | None | 0% | $705 |
| 2023 | 37 | 15 | None | 0% | $1,568 |
| 2022 | 84 | 35 | 13% (11) | 0% | $2,228 |
| 2021 | 73 | 15 | None | None | $5,933 |
| 2020 | 41 | 20 | None | 0% | $2,104 |
| 2019 | 21 | 13 | None | None | $422 |
| 2018 | 91 | 48 | None | 0% | $3,479 |
| 2017 | 169 | 68 | None | None | $5,163 |
| 2016 | 105 | 37 | 11% (11) | None | $5,059 |
| 2015 | 119 | 40 | None | None | $5,903 |
| 2014 | 146 | 53 | None | 16% | $9,187 |
| 2013 | 206 | 76 | None | 19% | $20,770 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Azelastine | 17 | $396 | $23 |
2022: 1 drug
| Azelastine | 38 | $1,257 | $33 |
2021: 2 drugs
| Ampicillin-Sulbactam | 41 | $4,035 | $98 |
| Azelastine | 13 | $696 | $54 |
2020: 1 drug
| Ipratropium | 12 | $1,543 | $129 |
2018: 2 drugs
| Azelastine | 28 | $910 | $32 |
| Mupirocin | 14 | $126 | $9 |
2017: 6 drugs
| Azelastine | 44 | $2,065 | $47 |
| Ipratropium | 12 | $319 | $27 |
| Amoxicillin-Clavulanate Potass | 20 | $206 | $10 |
| Mupirocin | 19 | $186 | $10 |
| Fluticasone Propionate | 14 | $176 | $13 |
| Ondansetron | 13 | $91 | $7 |
2016: 1 drug
| Azelastine | 13 | $673 | $52 |
2015: 3 drugs
| Azelastine | 15 | $993 | $66 |
| Mupirocin | 25 | $355 | $14 |
| Fluticasone Propionate | 14 | $153 | $11 |
2014: 4 drugs
| Nexium | 11 | $4,659 | $424 |
| Azelastine | 26 | $1,939 | $75 |
| Fluticasone Propionate | 25 | $437 | $17 |
| Mupirocin | 23 | $261 | $11 |
2013: 5 drugs
| Nexium | 19 | $8,444 | $444 |
| Azelastine | 33 | $2,553 | $77 |
| Lansoprazole | 19 | $2,009 | $106 |
| Fluticasone Propionate | 41 | $995 | $24 |
| Mupirocin | 18 | $205 | $11 |
Money from drug and device companies
$2,167 in 2025
| 2025 | 4 | 10 | $1,600 | $2,167 |
| 2024 | 6 | 21 | $20,250 | $22,151 |
| 2023 | 3 | 27 | $29,905 | $33,643 |
| 2022 | 4 | 22 | $19,880 | $21,937 |
| 2021 | 3 | 7 | $3,750 | $4,010 |
| 2020 | 2 | 14 | $17,061 | $18,255 |
| 2019 | 5 | 27 | $23,490 | $25,846 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Stealthstation S8 Platform | $1,868 | 5 payments
|
| GlaxoSmithKline | Nucala | $195 | 3 payments
|
| Integra LifeSciences | Acclarent Aera | $83 | 1 payment
|
| Stryker | Hemopore | $20 | 1 payment
|
See all 10 published payments
| Medtronic | Consulting · 2025-10-17 | Stealthstation S8 Platform | $800 |
| GlaxoSmithKline | Meals · 2025-10-12 | Nucala | $36 |
| Medtronic | Consulting · 2025-09-17 | None | $800 |
| Medtronic | Meals · 2025-08-07 | Propel | $167 |
| Integra LifeSciences | Meals · 2025-08-01 | Acclarent Aera | $83 |
| GlaxoSmithKline | Meals · 2025-07-11 | Nucala | $119 |
| Medtronic | Meals · 2025-02-03 | Propel | $28 |
| GlaxoSmithKline | Meals · 2025-02-02 | Nucala | $40 |
| Stryker | Meals · 2025-01-29 | Hemopore | $20 |
| Medtronic | Meals · 2025-01-27 | Propel | $74 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $22,151
| Medtronic | Endo-Scrub | $15,895 | 12 payments
|
| Genzyme | Dupixent | $4,250 | 1 payment
|
| Optinose US | Xhance | $1,576 | 2 payments
|
| Integra LifeSciences | Acclarent Aera | $205 | 2 payments
|
| Stryker | Core | $183 | 3 payments
|
| GlaxoSmithKline | Nucala | $41 | 1 payment
|
2023: $33,643
| Medtronic | Stealthstation S8 Platform | $27,800 | 23 payments
|
| Regeneron Pharmaceuticals | Dupixent | $4,305 | 2 payments
|
| Optinose US | Xhance | $1,538 | 2 payments
|
2022: $21,937
| Medtronic | Stealthstation S8 Platform | $19,007 | 18 payments
|
| Ethicon | Monocryl | $2,480 | 1 payment
|
| OptiNose US | Xhance | $298 | 2 payments
|
| Stryker | Xpress Ent Dilation System | $153 | 1 payment
|
2021: $4,010
| Regeneron Pharmaceuticals | Dupixent | $3,000 | 1 payment
|
| Medtronic | Aps | $990 | 5 payments
|
| Boston Scientific | Ekosonic | $21 | 1 payment
|
2020: $18,255
| Medtronic USA | Stealthstation | $17,655 | 13 payments
|
| OptiNose US | Xhance | $600 | 1 payment
|
2019: $25,846
| Stryker | Nse - Sonopet | $18,134 | 11 payments
|
| OptiNose US | Xhance | $3,705 | 3 payments
|
| Medtronic USA | Fusion | $3,615 | 10 payments
|
| Intersect ENT | Propel | $345 | 2 payments
|
| Covidien LP | Barrx | $48 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis Without the Presence of Nasal Polyps. Opn-Flu-Cs-3206. · 2020 | Their institution | $10,112 |
| Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis Without the Presence of Nasal Polyps. Opn-Flu-Cs-3206. · 2022 | Their institution | $4,956 |
| Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis Without the Presence of Nasal Polyps. Opn-Flu-Cs-3206. · 2023 | Their institution | $2,143 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2024 | This clinician | $867 |
| GENZYME CORPORATION · A Randomized, 24-Week Treatment, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on A Background Therapy With Intranasal Corticosteroids · 2022 | This clinician | $750 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1487814109
- Licence
- CA A112083, GA 65779, NY 246435California A112083: Current · expires 2027-09-30
- Trained
- Oregon Health Sciences University School of Medicine, 2005
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Otolaryngology (207Y00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-06-16
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.